Validated Targets Sample Clauses

Validated Targets. For the avoidance of doubt, the Parties agree that Theravance's existing programs set forth on Schedule 1.36 are each Discovery Programs directed at Validated Targets.
Sample 1Sample 2Sample 3
Validated Targets. During the term of the Program and the Lilly Development Program, Lilly shall diligently screen the Validated Targets to discover and develop Products. Lilly shall screen all Validated Targets within [**] of the date upon which the Validated Target milestone is paid to Millennium pursuant to Section 8.2. If a Validated Target is not screened within [**] of the payment of the milestone, then Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, and retain rights to therapeutic leads found by Millennium using such a Validated Target, and proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. After a Validated Target is first screened, Lilly shall screen said Validated Target at least once every [**]. For each Validated Target, Lilly will be deemed to be diligent under this Section 7.2 so long as Lilly presents a compound arising from a screen against such Validated Target to [**] from the use of the Validated Target in a screen. In the event Lilly does not screen against a specific Validated Target within the time period set forth above, or does not present a compound arising from said screen to [**] within the time specified, Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, provided, however, that such screening efforts shall be deemed to be a Non-Program Field Project subject to Lilly's rights under Section 5.2, except Lilly's rights thereto shall extend for [**] , Millennium may proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. Lilly shall not be required to continue to screen a Validated Target [**] from the Program in its development program (defined as a program that has been [**], or its successor) which (i) reacts with said Validated Target or which demonstrates the same clinical utility (and no significant clinical advantages) as a compound which reacts...
Sample 1
Validated Targets. 38 Section 7.4. Astra Minimum Efforts. ............................... 38 Section 7.5. Commercialization .................................... 38 Section 7.6. Niche Products ....................................... 39 (iii)
Sample 1
Validated Targets. This Schedule 3.1.5 will be amended by the Parties on or after the date on which any Initial Research Target, Definitive Research Target or Extended Research Target becomes a Validated Target pursuant to Section 3.1.
Sample 1
Validated Targets. During the term of the Research Program and the Astra Development Program, Astra shall use [**] to utilize each Validated Target to discover and develop Hits, Leads, Candidate Drugs and Products. Such efforts [**] in connection with [**] that are at [**] and that are of [**] and [**]. Within thirty (30) days after the end of each calendar half-year during the term of the Research Program and the term of the Astra Development Program, Astra shall provide Millennium with a written report describing Astra's progress in using Validated Targets to discover and develop Hits, Leads, Candidate Drugs and Products. If Astra fails to satisfy its diligence obligations as set forth in this Section 7.3, as agreed between the Parties or determined pursuant to the dispute resolution process as set forth in Section 12.2, with respect to any Validated Target, then Astra's exclusive rights with respect to therapeutic products that are identified through the use of such Validated Target, and the Candidate Gene from which it was derived, [**] (with Millennium, either alone or in collaboration with others) as [**].
Sample 1
Validated Targets. Incyte shall have the right to select up to [**] Initial Validated Targets and up to [**] Supplemental Validated Targets, for a total of up to seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1. Upon selection of seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1, the Option rights granted to Incyte in Section 3.1 shall be deemed to have been exhausted and no further Option rights shall remain in effect (for clarity, regardless of the periods for which Option rights were granted).
Sample 1
Validated Targets 
Sample 1

Related to Validated Targets

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Milestone Schedule Please state the status and progress of each Milestone and identify any completed Milestone(s) for the previous calendar quarter.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Project Scope The physical scope of the Project shall be limited to only those capital improvements as described in Appendix A of this Agreement. In the event that circumstances require a change in such physical scope, the change must be approved by the District Committee, recorded in the District Committee's official meeting minutes, and provided to the OPWC Director for the execution of an amendment to this Agreement.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Project Specific Milestones In addition to the milestones stated in Section 212.5 of the Tariff, as applicable, during the term of this ISA, Interconnection Customer shall ensure that it meets each of the following development milestones: 6.1 Substantial Site work completed. On or before October 1, 2020, Interconnection Customer must demonstrate completion of at least 20% of project site construction. At this time, Interconnection Customer must submit to Interconnected Transmission Owner and Transmission Provider initial drawings, certified by a professional engineer, of the Customer Interconnection Facilities. 6.2 Delivery of major electrical equipment. On or before October 1, 2020, Interconnection Customer must demonstrate that all generating units have been delivered to Interconnection Customer’s project site.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the sales milestone events (“Sales Milestone Events”) set forth below with respect to sales of such Co-Co Product in the ROW Territory. [***] [***] [***] [***]

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.